吡格列酮对三硝基苯磺酸诱导炎症性肠病大鼠过氧化物酶体增殖物激活受体γ和核因子-κB p65的影响  

Effects of pioglitazone on expression of PPAR-γ and NF-κB p65 in rats with inflammatory bowel disease induced by TNBS

作　　者：葛相栓[1] 刘小玲[1] 王慧超[1] 李君芳[2] GE Xiangshuan;LIU Xiaoling;WANG Huichao;LI Junfang(Department of Gastroenterology,Henan Honliv Hospital,Changyuan,Henan 453400,China;Department of Pathology,Henan Honliv Hospital,Changyuan,Henan 453400,China)

机构地区：[1]河南宏力医院消化科,河南长垣453400 [2]河南宏力医院病理科,河南长垣453400

出　　处：《安徽医药》2019年第10期1921-1925,I0001,共6页Anhui Medical and Pharmaceutical Journal

基　　金：河南省二〇一三科技发展计划(132102310415)

摘　　要：目的探讨吡格列酮对结肠炎保护作用及其可能机制。方法SD大鼠采用随机数字表法分为对照组、模型组、柳氮磺吡啶(SASP)药物治疗组(SASP组)、吡格列酮低、中及高剂量治疗组(其中SASP组与吡格列酮组为干预组),每组8只。模型组及干预组经肛灌入5%三硝基苯磺酸(TNBS)/乙醇5 mL/kg,对照组灌入0.85%氯化钠5 mL/kg,造模后第1天干预组给予SASP及不同剂量吡格列酮,对照组及模型组给予0.85%氯化钠10 mL/kg灌胃,统计炎症活动指数(DAI)、大体形态损伤指数(CMDI)、组织学损伤指数(TDI)的变化及免疫组织化学检测结肠过氧化物酶体增殖物激活受体γ(PPAR?γ)及核因子?κB p65(NF?κB p65)的表达。结果(1)模型组、SASP组、吡格列酮低、中、高剂量治疗组DAI值分别为(3.13±0.83)、(1.50±0.53)、(2.25±0.71)、(1.63±0.52)、(2.25±0.46),SASP组、吡格列酮低、中、高剂量治疗组低于模型组,P值分别是0.000、0.010、0.000、0.010;吡格列酮低、中、高剂量治疗组与SASP组比较,P值分别是0.020、0.690、0.020;(2)模型组、SASP组、吡格列酮低、中、高剂量治疗组CMDI分别是(2.63±0.52)、(1.13±0.83)、(1.38±0.52)、(1.13±0.83)、(1.63±0.84),SASP组、吡格列酮低、中、高剂量治疗组与模型组比较低于模型组,P值分别是0.000、0.001、0.000、0.005。吡格列酮低、中、高剂量治疗组与SASP组比较,P值分别是0.456、1.000、0.140;(3)模型组、SASP组、吡格列酮低、中、高剂量治疗组TDI分别是(9.50±1.93)、(4.63±1.19)、(5.00±1.31)、(4.75±1.04)、(4.00±0.76),SASP组、吡格列酮低、中、高剂量治疗组与模型组比较,均P=0.000,吡格列酮低、中、高剂量治疗组与SASP药物组比较,P值分别是0.568、0.849、0.568;(4)对照组、模型组、SASP组、吡格列酮低、中、高剂量治疗组PPAR?γ值分别是(46.62±3.07)、(27.24±2.71)、(39.79±1.39)、(34.62±2.26)、(40.13±2.23)、(36.22±2.11)。模型组表达低于对照组,P=Objective To discuss the function and mechanism of pioglitazone on inflammatory bowel disease.Methods SD rats were randomly assigned into the control group and the model group,the SASP drug treatment group(SASP group),the low?dose pi?oglitazone treatment group,the pioglitazone medium?dose treatment group,and the pioglitazone high?dose treatment group(among them,SASP group and pioglitazone group were intervention group)with 8 in each group.The model group and the intervention group were perfused with 5%trinitrobenzene sulfonic acid(TNBS)/ethanol 5 mL/kg,and the control group was filled with 0.85%sodium chloride 5 mL/kg.On the first day after modeling,the intervention group was given SASP and different doses of pioglitazone.The model group was given 0.85%sodium chloride 10 mL/kg,and the changes of inflammatory activity index(DAI),gross morpho?logical injury index(CMDI),tissue damage index(TDI)were detected and the expression of Peroxidosome proliferators activate re?ceptorγ(PPAR?γ)and Nuclear factorκB p65(NF?κB p65)in colon was detected by immunohistochemistry.Results(1)The DAI values of the model group,SASP group and pioglitazone low,medium and high dose treatment groups were(3.13±0.83),(1.50±0.53),(2.25±0.71),(1.63±0.52)and(2.25±0.46),respectively,and DAI values in SASP group,pioglitazone low,medium and high?dose treatment group were lower than those in the model group(P=0.000,0.010,0.000,and 0.010,respectively);the low,medium,and high doses of pioglitazone were compared with the SASP group,and the P values were 0.020,0.690,and 0.020,respectively;(2)The CMDI of the model,the low,medium and high doses of the group,SASP group and pioglitazone were(2.63±0.52),(1.13±0.83),(1.38±0.52),(1.13±0.83),and(1.63±0.84),respectively,and CMDI in SASP group and the low,medium and high doses of pioglitazone was lower than that in the model group(P=0.000,0.001,0.000,and 0.005,respectively).Compared with the SASP group,the low,medium and high doses of pioglitazone had a P value of 0.456,1.000,and 0.140,respectively.(3

关 键 词：炎性肠病 吡格列酮 过氧化物酶体增殖物激活受体 NF-κB 转录因子RelA 三硝基苯磺酸 柳氮磺胺吡啶 细胞保护 大鼠 Sprague-Dawley 

分 类 号：R57[医药卫生—消化系统]